Wednesday, January 17, 2024

Tr1X Gets $75M In Series A

San Diego-based biotech developer Tr1X, a company developing therapies to treat autoimmune disease, announced this morning that it has raised $75M in a Series A financing round. The funding was led by The Column Group, and also included NEVA SGR and Alexandria Ventures. The company says it is developing allogeneic engineered Treg and CAR-Treg cell therapies to treat major autoimmune diseases.